A popular injectable birth control, Depo-Provera (medroxyprogesterone acetate) — also sold as Depo-SubQ Provera 104 — has long been favored for its 99% effectiveness and ease of use compared to daily ...

The Depo-Provera birth control shot has been linked to an increased risk of a type of brain tumors known as meningiomas. Women who received the Depo shot and were diagnosed with meningioma brain ...

A March 2024 study published by The BMJ revealed that women who were injected with Depo-Provera (medroxyprogesterone acetate) are more than five times more likely to be diagnosed with a type of brain ...

The Food and Drug Administration approved on Friday a label change for Pfizer's birth control shot Depo-Provera that warns patients of the risk of meningioma, a tumor in the lining of the brain.

The decision comes as Pfizer faces lawsuits from more than 1000 women who say the company knew about the risks and didn’t warn them. The agency signed off last week on a label update for 2 versions of ...

The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE: PFE) Depo-Provera contraceptive injection, adding a warning about the risk of meningioma, a type of ...

According to the Centers for Disease Control and Prevention (CDC), as of 2017, 65.3% of women between the ages of 15 and 49 in the United States use a form of birth control. Of this population, 10.4% ...

March 31, 2005 — The U.S. Food and Drug Administration (FDA) has approved a once-monthly formulation of ibandronate sodium for the treatment and prevention of postmenopausal osteoporosis; entecavir ...